PGT-M: Testing Embryos for a Known Genetic Condition

Preimplantation genetic testing for monogenic disease, known as PGT-M, checks embryos for a particular condition caused by a change in one gene. The test is performed on embryos made through in vitro fertilisation (IVF), before a selected embryo is transferred to the uterus. It is designed around a known family diagnosis or genetic variant, rather than being a general check for every possible condition.

A fertility specialist and genetic counsellor first confirm which variant the laboratory must look for. The laboratory may need genetic information from both partners and, in some families, other relatives. PGT-M can reduce the chance of transferring an embryo affected by the specified condition, but it does not replace pregnancy testing or routine antenatal screening.

Treatment usually begins with genetic counselling and a review of the family diagnosis. The IVF team then stimulates the ovaries, collects eggs, and combines eggs with sperm to create embryos. When an embryo reaches the appropriate laboratory stage, specialists remove a small group of cells for testing and freeze the embryo while results are prepared. The report helps the team discuss which embryos are suitable for consideration. If you proceed, a clinician prepares the uterine lining and transfers a chosen embryo in a separate step. A pregnancy test follows the transfer.

PGT-M requires IVF, egg collection, embryo biopsy, and an embryo transfer, so the relevant risks include those of fertility treatment and a procedure. Ovarian stimulation can cause discomfort and requires monitoring; egg collection involves a medical procedure. Embryo biopsy is performed by an embryology team, but not every embryo will produce a usable result or develop for transfer. PGT-M lowers the chance of transferring an embryo affected by the tested condition, yet it cannot identify every health or developmental problem. Confirmatory prenatal testing is usually discussed after pregnancy.

You can discuss whether to pursue IVF with PGT-M, IVF without PGT-M, or another family-building route. Some people choose testing because a specific inherited condition has affected relatives, a previous child, or a pregnancy. Others prefer to conceive naturally and consider prenatal diagnostic testing. The decision can involve the accuracy and limits of the test, the number of embryos available, treatment burden, personal beliefs, and how you would use results. Genetic counselling can help you compare options without directing you toward one choice.

PGT-M is targeted: the laboratory needs a defined condition or gene variant to test. Results are interpreted alongside embryo development and the couple’s clinical circumstances. A result described as suitable for transfer does not mean the embryo is free from all genetic conditions. The fertility team should explain how results are reported, whether testing can be repeated, and what follow-up is advised.

PGT-M may be discussed when one or both partners carry a known disease-causing variant, when a child or close relative has a monogenic condition, or when a previous pregnancy was affected. Couples with related family backgrounds may also seek genetic assessment before deciding whether targeted embryo testing is relevant. A carrier result alone does not automatically mean PGT-M is needed; the inheritance pattern and the condition’s implications must be reviewed.

Genetic carrier screening can be a useful earlier conversation when the family variant is not yet known. For families affected by thalassaemia or a history of recurrent miscarriage, a specialist can explain whether targeted testing is appropriate.

The pathway is planned jointly by fertility, genetics, and laboratory teams. First, the family variant is verified and a test is prepared. Next, IVF medication, egg collection, fertilisation, embryo culture, and biopsy take place. Embryos are generally kept in the laboratory while the genetic result is interpreted. The clinician then reviews which embryos can be considered, obtains consent, and plans transfer or a future frozen transfer. Pregnancy follow-up includes a test and a conversation about confirmatory diagnostic testing.

Recovery is mainly related to ovarian stimulation and egg collection because embryo testing itself does not involve an operation on your body. Mild cramping, bloating, or tiredness can occur after collection. Your clinic will give individual instructions about activity, medicines, warning symptoms, and the timing of transfer. Contact the team promptly for severe pain, heavy bleeding, breathing difficulty, or rapidly worsening swelling.

PGT-M may not give a result for every embryo, and some embryos may not be suitable for transfer for developmental or genetic reasons. The test can have technical limitations, including uncertainty that requires further discussion. IVF may involve medication effects, a response requiring urgent assessment, or complications from egg collection. Pregnancy can still have genetic or medical concerns unrelated to the tested condition, so prenatal care remains necessary.

Depending on your diagnosis and circumstances, alternatives may include trying to conceive without embryo testing, using prenatal diagnostic testing during pregnancy, donor eggs or sperm, donor embryos, adoption, or choosing not to pursue pregnancy. A genetics professional can explain how each option relates to the inheritance pattern and your priorities.

Look for a fertility service that can coordinate reproductive medicine, genetic counselling, and an accredited genetics laboratory. Ask who confirms the family variant, how results are explained, what happens when no embryo is suitable, and which prenatal follow-up is offered. Bring previous genetic reports or family diagnoses to the appointment if available.